Loading . . .
Press Conference


阅读以下关于PerkinElmer 的最近文章,请点击标题链接进入媒体网站查看全文。

PerkinElmer Meets 3Q Profit Forecasts

PerkinElmer Inc. (PKI) on Thursday reported third-quarter profit of $42.3 million. The results met Wall Street expectations. The average estimate of analysts surveyed by Zacks Investment Research was also for earnings of 57 cents per share.

PerkinElmer Boosts Lab IT Services with Ceiba Solutions Purchase

Ceiba’s managed services, certification, and informatics technologies will be integrated into PKI’s OneSource Lab IT portfolio, which includes lab computing, scientific application and data services, and computer systems validation.

Elements: A New Approach to Collaborative Science

Take a tour through Elements as PerkinElmer demonstrates this new platform. Share research results with colleagues globally, review comments, gather input, and explore the ways in which Elements can help you with your research effectively.

PerkinElmer Launches Optical Imaging System

Perkin Elmer has unveiled its Solaris quantitative optical molecular imaging system for use in small and large animal studies. The Solaris system can bridge molecular imaging research techniques to support potential clinical outcomes.

A Case for Co-Sourcing

After a generation of outsourcing services to lower-cost providers, smart companies now realize that they need to reassess this strategy. Outsourcing did lower costs in a time of need, but it came at a high price.

Informatics Fosters 'Science as a Service'

Several forces are bringing into focus a future that includes the democratization of data, where individuals will be evaluating, analyzing, and making decisions from an abundance of data that is delivered right into their hands.

SCID Previously Underdiagnosed in Infants with Fatal Infections

Severe combined immunodeficiency (SCID), a potentially life-threatening disorder affecting infants, is twice as common as previously believed, according to a new study that is the first to examine the impact of this newborn screening test.

Reflections on ChemDraw

ChemDraw, the software program used by chemists worldwide to draw molecular structures, was originally invented to save Dave and Sally Evans’s marriage.

Automated Gel Electrophoresis Systems

PerkinElmer Inc. has introduced its LabChip GX Touch and GXII Touch automated electrophoresis systems. The LabChip platform’s key feature is automation of conventional gel electrophoresis, eliminating the need for manual sample preparation.

Measuring Orientation in Polymer Films

The mechanical properties of polymer films such as tensile strength and resistance to tearing depend strongly on the orientation of the polymer chains.

The Revival of Environmental Instrumentation

Advances in the design of ICP-MS, triple quad LCMS, and handheld instruments give researchers the ability to detect trace-level contaminants unmeasurable in the past.

Sofie and PerkinElmer to Market Preclinical Hybrids, Biopharmaceuticals

PerkinElmer announced an agreement with Sofie Biosciences to commercialize the latter's preclinical PET, 3D CT, and X-ray systems. The partnership will be focusing on areas of research in pharmacology, oncology, immunology, cardiology and neurobiology.

PerkinElmer Launches New Version of ChemBioOffice Suite

The ChemBioDraw® Ultra program is a digital drawing tool that chemists and biologists use to create publication-ready, scientifically intelligent drawings for use in electronic lab notebooks (ELNs), databases and publications.

Innovators Honored by I.F.T.

Three industry suppliers — Arla Foods Ingredients, PerkinElmer, and Solazyme — each earned a 2014 Institute of Food Technologists Expo Innovation Award.

Labs Embrace Automated Liquid Handling

Many laboratories are realizing significant gains in efficiency, thanks to automated liquid-handling technology that delivers accurate and precise dispensing of volumes in the nanoliter range.

PerkinElmer to Help Promote Newborn Screening in Rural China

PerkinElmer will collaborate with China’s National Health and Family Planning Commission in an exclusive agreement to develop a three-year newborn screening training program to detect life-threatening disorders.